Corxel Pharmaceuticals has acquired an oral small molecule GLP-1 agonist with potential applications in obesity and diabetes. The Phase 2-ready pill could compete with oral metabolic meds in development by companies such as Roche, AstraZeneca, and Structure Therapeutics.
The post The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender appeared first on MedCity News.
Leave a comment